Regeneron Pharmaceuticals Stock Price - REGN

Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Regeneron Pharmaceuticals Inc REGN NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  -2.74 -0.79% 342.54 342.79 336.17 341.20 345.28 11:37:06
Bid Price Ask Price Spread Spread % News
342.37 342.78 0.41 0.12% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
6,105 336,850 $ 339.77 $ 114,452,397 768,304 271.37 - 445.00
Last Trade Time Type Quantity Stock Price Currency
11:37:06 1 $ 342.64 USD

Regeneron Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 37.22B 109.80M $ 2.44B 21.30 20.40 108.64M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Regeneron Pharmaceuticals News

Loading Messages....

Latest REGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical REGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week385.90386.31336.17356.861,135,341-43.36-11.24%
1 Month373.74396.47336.17371.95712,773-31.20-8.35%
3 Months313.05396.47310.74361.16784,18529.499.42%
6 Months314.50396.47271.37327.67709,57628.048.92%
1 Year415.11445.00271.37340.22741,506-72.57-17.48%
3 Years342.34543.5518271.37372.97795,1050.200.06%
5 Years418.72605.9299271.37399.29791,559-76.18-18.19%

Regeneron Pharmaceuticals Description

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis, asthma, and nasal polyposis; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.